<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322632</url>
  </required_header>
  <id_info>
    <org_study_id>280-01</org_study_id>
    <nct_id>NCT02322632</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions</brief_title>
  <official_title>An Open-label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Paricalcitol Capsules 4 mcg of Dr. Reddy's Laboratories Limited and Zemplar Capsules, 4 mcg of Abbott Laboratories, USA in Healthy, Adult, Human Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose,
      crossover oral bioequivalence study in healthy subjects under fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose,
      crossover oral bioequivalence study of Paricalcitol Capsules 4 mcg of Dr. Reddy's
      Laboratories Limited and Zemplar® Capsules 4 mcg of Abbott Laboratories, USA in healthy,
      adult, human subjects under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve</measure>
    <time_frame>0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0 and 60.0 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Paricalcitol Capsules, 4 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zemplar Capsules, 4 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zemplar Capsules, 4 mcg of Abott Laboratories USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol Capsules, 4 mcg</intervention_name>
    <description>Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Paricalcitol Capsules, 4 mcg</arm_group_label>
    <arm_group_label>Zemplar Capsules, 4 mcg</arm_group_label>
    <other_name>Zemplar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, adult, human volunteers between 18 and 55 years of age (both inclusive)
             living in and around Ahmedabad city of western part of India.

          -  Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as
             weight in kg/height in m2.

          -  Have no significant diseases or clinically significant abnormal findings during
             screening, medical history, clinical examination, laboratory evaluations, 12- lead ECG
             and X-ray chest (postero-anterior view) recordings.

          -  Volunteers who have normal calcium, phosphorous status and no hypertensive status in
             order to avoid effect on vitamin D concentration in blood.

          -  Able to comply with the study procedures, in the opinion of the Principal
             investigator.

          -  Able to give voluntary informed consent for participation in the trial.

        In case of female subjects*:

          -  Surgically sterilized at least 6 months prior to study participation; Or

          -  If of child bearing potential is willing to use a suitable and effective double
             barrier contraceptive method or intra uterine device during the study.

          -  Urine pregnancy test (for female subjects*) must be negative at the time of screening.
             *No female subjects were enrolled in the study.

        Exclusion Criteria:

          -  Known hypersensitivity or idiosyncratic reaction to Paricalcitol or to any of its
             excipients or any drug or any substance.

          -  History or presence of any disease or condition which might compromise the
             haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular,
             immunological, dermatological, gastrointestinal or any other body system.

          -  Ingestion or Use of any medication at any time in 14 days prior to dosing. In any such
             case subject selection will be at the discretion of the Principal Investigator.

          -  Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or
             NSAID induced urticaria.

          -  Consumption of Grapefruits or its products within a period of 48 hours prior to
             check-in.

          -  A recent history of harmful use of alcohol(less than 2 years), i.e. alcohol
             consumption of more than 14 standard drinks per week for men and more than 7 standard
             drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of
             wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc). &quot; or
             consumption of alcohol or alcoholic products within 48 hous prior to check-in.

          -  Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from
             smoking during the study.

          -  The presence of clinically significant abnormal laboratory values during screening.

          -  Use of any recreational drugs or history of drug addiction or testing positive in
             pre-study drug scans.

          -  History or presence of psychiatric disorders.

          -  A history of difficulty with donating blood.

          -  Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal
             product or participation in a drug research study within a period of 90 days prior to
             the first dose of study medication. Elimination half-life of the study drug should be
             taken into consideration for inclusion of the subject in the study. Note: In case the
             blood loss is ≤ 200 mL, subject may be enrolled 60 days after blood donation or last
             sample of the previous study.

          -  A positive hepatitis screen including hepatitis B surface antigen and anti- HCV
             antibodies.

          -  A positive test result for anti-HIV antibody.

          -  An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to
             receiving the study drug and throughout the subjects' participation in the study. In
             any such case subject selection will be at the discretion of the Principal
             Investigator. Nursing mothers (females)*. *No female subjects were enrolled in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Pankaj Kumar Jha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>3 80 061</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

